Back to discover
Drug

Squalene

In clinical development
Emerging researchEarly-to-mid development

Also known as Spinacene, Supraene, (E,E,E,E)-Squalene, (all-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene.

1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Squalene
Aliases & brands
SpinaceneSupraene(E,E,E,E)-Squalene(all-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
RxNorm CUI
10014
ChEMBL ID
CHEMBL458402
UNII
7QWM220FJH

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
LATEST COMPLETION 2013
1
Completed
PHASE DISTRIBUTIONn = 1
Phase 11

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Adjuvants, Immunologic1Immunogenicity, Vaccine1
Journals, researchers & institutions
Top journals
  • Vaccine1
Leading researchers
  • Chu L1
  • Collins H1
  • Drame M1
  • Frenette L1
  • Friel D1
  • Innis BL1
  • Madan A1
  • Schuind A1
Leading institutions
free-text, unnormalised
  • 1250 South Collegeville Road1
  • Clinical Research Inc.1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across the same disease area as Squalene in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Squalene in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials